Australia's most trusted
source of pharma news
Friday, 18 July 2025
Posted 18 July 2025 AM
Johnson & Johnson Innovative Medicine has seen off the threat of Stelara losing patent protection, with record-breaking revenue of more than US$15 billion last quarter across its pharmaceutical portfolio.
Total revenue for the Innovative Medicine segment grew 4.9 per cent in the second quarter of 2025 compared to the same period in 2024, adding US$712 million in sales and surpassing US$15 billion for the first time.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.